Predicting Plaque Growth Using Blood Flow Stress Markers: A Proof-of-Concept Study
NCT07864051
Summary
Coronary artery disease occurs when fatty deposits (plaques) build up inside the arteries that supply blood to the heart. Some plaques remain stable, while others continue to grow or become more likely to rupture, which can lead to a heart attack. Identifying plaques that are at higher risk of progression could help doctors provide earlier and more personalized treatment. The purpose of this study is to determine whether combining information about blood flow within the coronary arteries with information about a person's biological response to blood flow can improve prediction of plaque growth. Participants undergoing treatment for coronary artery disease will have a specialized heart scan to assess blood flow patterns around plaques in their coronary arteries. Researchers will also collect blood samples to study cells that line blood vessels and investigate how these cells respond to blood flow forces. The study will follow participants over time to determine whether plaques are more likely to progress in individuals who show a stronger biological response to abnormal blood flow. The findings may help researchers develop new ways to identify patients at higher risk of future heart problems and support the development of more personalized approaches to prevention and treatment of coronary artery disease.
Eligibility
Inclusion Criteria: 1. Age ≥40 2. Stable angina, defined as typical symptoms with evidence of reversible ischemia in non-invasive test and/or documented obstructive coronary artery disease on coronary angiography (\>70% stenosis of at least one major epicardial coronary artery or positive fractional flow reserve study) 3. Patient that is willing and can provide written informed consent. Exclusion Criteria: 1. Acute coronary syndrome within \<3 months 2. Estimated glomerular filtration rate (eGFR) \<60ml/min/1.73m² 3. Previous coronary artery bypass surgery 4. Decompensated heart failure, or left ventricular ejection fraction ≤30% 5. Patient allergic to contrast or cannot receive treatment with aspirin, heparin, or thienopyridines 6. Anticipated life expectancy \<2 years 7. Flow limiting coronary artery disease in the proximal segments of all the 3 epicardial coronaries 8. History of heart transplantation 9. Patient that requires surgical revascularization 10. Extensive coronary artery disease (i.e., multiple chronic total occlusions) or tortuous coronary anatomy that does not allow assessment of the coronary arteries with intravascular imaging 11. Pregnant women will be excluded. All women of childbearing potential will undergo a pregnancy risk assessment and a urine pregnancy test prior to the 12-month PCCTA scan, in line with standard clinical practice for all PCCTA scans.
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07864051